In contrast, GLP-1-R agonists effectively reduce stroke events in patients with T2DM and established ASCVD, and thus have been implemented into recommendations for the stroke prevention of several associations, such as the American Stroke Association [9]. The gene discussed is GLP1R; the disease is atherosclerosis.